Pembrolizumab (MK-3475) for previously treated metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: Phase II KEYNOTE-180 study.
Explore this paper's citation graph
- Type
- article
- Published
- 2016-02-01
- Cited by
- 7
- References
- 0
- OpenAlex
- https://openalex.org/W4238006225
Keywords
Medicine, Pembrolizumab, Response Evaluation Criteria in Solid Tumors, Internal medicine, Esophagus
References
No references recorded for this paper.
Cited by
- Biologic therapy in esophageal and gastric malignancies: current therapies and future directions.
- Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma.
- microRNA 125a Regulates MHC-I Expression on Esophageal Adenocarcinoma Cells, Associated With Suppression of Antitumor Immune Response and Poor Outcomes of Patients.
- A case report of pseudo-progression after pembrolizumab in metastatic gastric cancer and a review of immunotherapy in gastroesophageal tumors
- Pembrolizumab in the Treatment of Metastatic Gastric Cancer
- PD-1 Inhibitor Plus Chemotherapy Versus Chemotherapy as First-line Treatment for Advanced Esophageal Cancer: A Systematic Review and Meta-Analysis
- PD-1 Inhibitor Plus Chemotherapy Versus Chemotherapy for First-Line Treatment in Advanced Esophageal Cancer: A Systematic Review and Meta-Analysis.
Related papers
- Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma
- 48TiPKEYNOTE-122: Phase 2 study of pembrolizumab versus standard-of-care chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal carcinoma
- Comparison of different tumor response criteria in patients with hepatocellular carcinoma after systemic therapy with the multikinase inhibitor sorafenib.
- The RECIST criteria compared to conventional response evaluation after peptide receptor radionuclide therapy in patients with neuroendocrine neoplasms
- Application of circulating tumor cells detection in chemotherapeutic efficacy evaluation of non-small cell lung cancer
- Comparison of response evaluation criteria in solid tumors (RECIST), European Association for the study of the liver (EASL) and modified RECIST criteria in evaluation of tumor response after transarteriai chemoembolization of primary liver cancer
- 168P Response assessments in hepatocellular carcinoma: What are the best criteria to utilize? mRECIST or RECIST 1.1? A retrospective meta-analysis of multiple phase III trials
- Feasibility of RECIST-based real-world tumor response assessment in metastatic non-small cell lung cancer patients.
- Comparison of Response Evaluation in Patients with Gastroenteropancreatic and Thoracic Neuroendocrine Tumors After Treatment with [177Lu-DOTA0,Tyr3]Octreotate
- EP1.04-30 RECIST and iRECIST Comparison in a Cohort of Patients with Advanced NSCLC Treated with Immunotherapy: Preliminary Study